LB Pharmaceuticals Files for IPO

Dow Jones

08/23

By Kelly Cloonan

LB Pharmaceuticals has filed for an initial public offering.

The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday.

The company didn't disclose the expected price or size of the offering.

LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters.

The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression.

The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products.

Write to Kelly Cloonan at kelly.cloonan@wsj.com

(END) Dow Jones Newswires

August 22, 2025 17:28 ET (21:28 GMT)

Copyright (c) 2025 Dow Jones & Company, Inc.

应版权方要求，你需要登录查看该内容

登录 / 注册

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2561834532"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2561834532\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2561834532?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-23 05:28","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2561834532","market":"hk","top_or_hot":-1,"title":"LB Pharmaceuticals Files for IPO","media":"Dow Jones","content":"<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LB Pharmaceuticals has filed for an initial public offering. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n</p>\n<p>\n  The company didn't disclose the expected price or size of the offering. \n</p>\n<p>\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and <a href=\"https://laohu8.com/S/SFB\">Stifel</a> are listed as the offering's underwriters. \n</p>\n<p>\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n</p>\n<p>\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 22, 2025 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>LB Pharmaceuticals Files for IPO</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nLB Pharmaceuticals Files for IPO\n</h2>\n\n<h4 class=\"meta\">\n\n\n<div class=\"head\" \">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Dow Jones </p>\n<p class=\"h-time\">2025-08-23 05:28</p>\n</div>\n\n</div>\n\n\n</h4>\n\n</header>\n<article>\n<font class=\"NormalMinus1\" face=\"Arial\">\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  By Kelly Cloonan \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  LB Pharmaceuticals has filed for an initial public offering. \n</p>\n<p>\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n</p>\n<p>\n  The company didn't disclose the expected price or size of the offering. \n</p>\n<p>\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and <a href=\"https://laohu8.com/S/SFB\">Stifel</a> are listed as the offering's underwriters. \n</p>\n<p>\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n</p>\n<p>\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n</p>\n<pre style=\"white-space: pre\">\n \n</pre>\n<p>\n  (END) Dow Jones Newswires\n</p>\n<p>\n  August 22, 2025 17:28 ET (21:28 GMT)\n</p>\n<p>\n  Copyright (c) 2025 Dow Jones &amp; Company, Inc.\n</p>\n</font>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4213","symbol_name":"石油与天然气的勘探与生产","start_time":0,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","article_id":"2561834532","we_media_id":"106","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2561834532","pubTimestamp":1755898080,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Dow Jones","introduction":"Dow Jones publishes the world’s most trusted business news and financial information in a variety of media.","home_visible":0,"id":"106","head_image":"https://static.tigerbbs.com/150f88aa4d182df19190059f4a365e99"},"summary":"LB Pharmaceuticals has filed for an initial public offering.The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday.The company didn't disclose the expected price or size of the offering.LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters.The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression.The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4213":"石油与天然气的勘探与生产","BK4233":"房地产运营公司","LB":"LandBridge Co. LLC"},"translate_title":"LB制药申请首次公开募股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"LB":1},"content_text":"By Kelly Cloonan \n\n\n \n\n\n  LB Pharmaceuticals has filed for an initial public offering. \n\n\n  The clinical-stage biopharmaceutical company said it intends to apply to have its units listed on the Nasdaq Global Market under the ticker LBRX, according to a filing with the Securities and Exchange Commission on Friday. \n\n\n  The company didn't disclose the expected price or size of the offering. \n\n\n  LB Pharmaceuticals has also granted underwriters a 30-day option to purchase additional units to cover over-allotments. Leerink Partners, Piper Sandler and Stifel are listed as the offering's underwriters. \n\n\n  The company intends to use the proceeds from the offering to advance the clinical development of its treatments for acute schizophrenia and bipolar depression. \n\n\n  The company recorded a loss of $63.1 million, or $6.20 a share, in 2024, compared to a loss of $6.3 million, or 78 cents a share, in the prior year. It has no product candidates approved for commercial sale and hasn't generated any revenue from the sale of products. \n\n\n \n\n\n  Write to Kelly Cloonan at kelly.cloonan@wsj.com \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  August 22, 2025 17:28 ET (21:28 GMT)\n\n\n  Copyright (c) 2025 Dow Jones & Company, Inc.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":true,"code":"91000000","status":"200"}}}